Wang Shou-li, Sun Fei, Zhao Xin, Chen Li-liang, Feng Guo-bin, Yan Cheng-hui, Han Ya-ling
Department of Cardiology, 306th Hospital of People's Liberation Army, Beijing 100101, China.
Zhonghua Xin Xue Guan Bing Za Zhi. 2010 Oct;38(10):870-4.
To observe the dynamic changes of plasma matrix metalloproteinases (MMPs) and investigate the effect of early or delayed percutaneous coronary intervention (PCI) in the presence or absence cilostazol on left ventricle (LV) remodeling in patients with non-ST elevation myocardial infarction (NSTEMI).
One hundred and sixty-four patients undergoing PCI with NSTEMI were randomized to early PCI (PCI within 24 h) group or delayed PCI group (PCI after 36 h), and patients in both group were further assigned to cilostazol or no cilostazol group. Plasma MMP-2 and MMP-9 concentrations were measured at 2, 4 days and 2 and 4 weeks after PCI. Left ventricular end-diastolic volume (LVEDV), left ventricle ejection fraction (LVEF), left ventricle posterior wall (LVPW) and interventricular septum (IVS) were measured by echocardiography at baseline and 1 year after PCI.
MMP-2 concentration at 2 weeks after PCI is higher than that at 2, 4 days and 4 weeks after PCI. MMP-9 concentration at 4 days is higher than that at 2 days, 2 weeks and 4 weeks after PCI. MMP-2 and MMP-9 were significantly lower in cilostazol group compared with that in non-cilostazol group at 4 days, 2 weeks and 4 weeks after NSTEMI (all P < 0.05). Changes of LVEDV and LVEF were significantly less in cilostazol group and early PCI group than that in no cilostazol group and delay PCI group (P < 0.05 or P < 0.01) at 1 year after NSTEMI.
Early PCI and Cilostazol use are associated with less LV remodeling in patients with NSTEMI. Cilostazol attenuated LV remodeling possibly by reducing concentration of MMP-2 and MMP-9 after PCI.
观察血浆基质金属蛋白酶(MMPs)的动态变化,并研究在有或无西洛他唑存在的情况下,早期或延迟经皮冠状动脉介入治疗(PCI)对非ST段抬高型心肌梗死(NSTEMI)患者左心室(LV)重构的影响。
164例行PCI的NSTEMI患者被随机分为早期PCI组(24小时内进行PCI)或延迟PCI组(36小时后进行PCI),两组患者再进一步分为西洛他唑组或无西洛他唑组。在PCI后2天、4天以及2周和4周时测定血浆MMP-2和MMP-9浓度。在基线时以及PCI后1年通过超声心动图测量左心室舒张末期容积(LVEDV)、左心室射血分数(LVEF)、左心室后壁(LVPW)和室间隔(IVS)。
PCI后2周时MMP-2浓度高于PCI后2天、4天和4周时。PCI后4天时MMP-9浓度高于PCI后2天、2周和4周时。NSTEMI后4天、2周和4周时,西洛他唑组的MMP-2和MMP-9明显低于无西洛他唑组(所有P<0.05)。NSTEMI后1年时,西洛他唑组和早期PCI组的LVEDV和LVEF变化明显小于无西洛他唑组和延迟PCI组(P<0.05或P<0.01)。
早期PCI和使用西洛他唑与NSTEMI患者较少的左心室重构相关。西洛他唑可能通过降低PCI后MMP-2和MMP-9的浓度来减轻左心室重构。